AnaptysBio, Inc. , a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Anaptysbio stock last closed at $46.91, up 1.75% from the previous day, and has increased 32.44% in one year. It has overperformed other stocks in the Biotechnology industry by 0.96 percentage points. Anaptysbio stock is currently +54.97% from its 52-week low of $30.27, and -36% from its 52-week high of $73.30.
As of Nov 2, 2026, there are 29.9M ANAB shares outstanding. The market value of ANAB is $1.40B. In the last 24 hours, 281,000 ANAB shares were traded.
How to Buy Anaptysbio Stock
Wondering how to invest in Anaptysbio stock? Here's how.
Decide where to buy Anaptysbio stock: You need to decide on a stock brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy Anaptysbio stock.
Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
Deposit funds into your brokerage account: Select your payment method and add your information.
Analyze Anaptysbio stock: The Anaptysbio ticker symbol is ANAB. Is Anaptysbio stock a good investment? Should you buy shares of ANAB? How do ANAB's underlying business fundamentals look? Do top analysts think Anaptysbio is a good buy? Why has ANAB's stock price moved recently? (Hint: Our stock market research tools can help you figure out if ANAB is a good stock to buy).
Place your ANAB buy order: Decide if you will purchase ANAB shares at the current market price or use a limit order to purchase ANAB stock at a specific price.
Get the latest news on your ANAB position: Create a watchlist to get the latest news on your position in Anaptysbio stock.
Step 1: Decide where to buy Anaptysbio stock
You will need a brokerage account to access the NASDAQ market and buy ANAB shares.
A brokerage account is an investment account that allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
We believe that eToro is the best online stock brokerage. Here's why:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to world markets: From Tech to Financial Services, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create a brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal information so you are able to invest in ANAB stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Anaptysbio stock
Once you have decided on the best place to buy Anaptysbio stock, it's absolutely critical to research their stock prior to buying, so you actually comprehend the risk as well as the upside.
Anaptysbio shares quick numbers
ANAB Price
$46.91
1w %
-3.83%
1y %
32.44%
5y %
40.3%
P/E
6.94x
P/B
132.49x
P/S
5.78x
PEG
N/A
Revenue
$237.61M
Earnings
$195.72M
Fore. Rev. Growth
-3.96%
Fore. Earn. Growth
-35.24%
Market Cap
$1.40B
Next Earnings
N/A
Next Dividend
N/A
ANAB Due Diligence Checks
WallStreetZen was created to help part-time investors perform more accurate fundamental analysis in less time.
ANAB profit margin has gone up from -107.7% to 82.4% in the past year.
ANAB earnings of $14.96M is not sufficient to cover its interest payments.
There are more short-term assets than short-term liabilities on the ANAB balance sheet.
Cons:
There are more long-term liabilities than short-term assets on the ANAB balance sheet.
ANAB's operating cash flow of $18.08M allows it to safely service it's debt of $269.59M.
Total ANAB debt is higher than 5 years ago, relative to shareholder equity.
ANAB has a relatively high debt to equity ratio of 28.95.
Is it a good time to buy ANAB stock, according to Wall Street analysts?
Out of 7 sell side analysts who give forecasts on ANAB, the consensus analyst rating on Anaptysbio is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent ANAB Analyst Forecasts
Etzer Darout, a top 2% analyst from Barclays maintains ANAB with a strong buy rating and raises their ANAB price target from $63.00 to $75.00, on May 13, 2026.
Barclays's Etzer Darout raised their price target on Anaptysbio (NASDAQ: ANAB) by 19% from $63 to $75 on 2026/05/13. The analyst maintained their Strong Buy rating on the stock.
AnaptysBio reported its Q1 2026 earnings.
Raising their price target, Darout big-pictured that the company continues to execute on its strategy to capitalize on the Jemperli royalty stream.
Earnings Report
For Q1 2026, AnaptysBio reported:
EPS of $(1.84), which missed Q1 2026's $(1.28).
Revenue of $25.56M, which missed Q1 2025's $27.77M.
Management did not provide financial guidance in its press release.
President & CEO Daniel Faga commented: “Following the completion of the spin-off of First Tracks Bio in late April, Anaptys now exclusively manages the financial collaborations for Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses, and delivering an EBIT margin greater than 95%.
“With Chris Murphy joining as CFO, who brings deep business development and investment banking experience, our priority continues to be to protect our two royalty streams and return their value to shareholders.”
Yasmeen Rahimi, a top 6% analyst from Piper Sandler maintains ANAB with a strong buy rating and lowers their ANAB price target from $95.00 to $93.00, on May 4, 2026.
Last year, ANAB revenue was $237.61M. In the last 5 year, ANAB's revenue has gone up by 18.6% per year. This was slower than the Biotechnology industry average of 29.76%.
No, Anaptysbio doesn't provide an income stream by paying out dividends.
What others are saying about ANAB
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Place your ANAB buy order
There are two main types of orders:
Market order: A market order is an order to buy or sell a stock at the best possible price. Market orders are mostly the best for newer investors.
Limit order: A limit order lets you buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a given price limit, use a limit order.
Press the Open Trade button and your broker will execute your order.
If you want additional help with buying stocks on eToro, click the how to video below:
How much does it cost to buy one Anaptysbio share?
As of Nov 2, 2026, it costs $46.91 to buy one share of Anaptysbio stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.213 shares of ANAB.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.